ADPT
NASDAQ · Life Sciences Tools & Services
Adaptive Biotechnologies
$23.11
+0.54 (+2.39%)
Financial Highlights (FY 2026)
Revenue
311.97M
Net Income
-67,021,892
Gross Margin
74.2%
Profit Margin
-21.5%
Rev Growth
+14.3%
D/E Ratio
0.60
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 74.2% | 74.2% | 29.3% | 29.3% |
| Operating Margin | -20.6% | -18.6% | 12.2% | 13.6% |
| Profit Margin | -21.5% | -20.4% | 14.0% | 10.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 311.97M | 272.85M | 1.18B | 1.15B |
| Gross Profit | 231.61M | 202.56M | 346.79M | 336.38M |
| Operating Income | -64,328,493 | -50,634,636 | 144.00M | 155.55M |
| Net Income | -67,021,892 | -52,754,681 | 166.04M | 120.97M |
| Gross Margin | 74.2% | 74.2% | 29.3% | 29.3% |
| Operating Margin | -20.6% | -18.6% | 12.2% | 13.6% |
| Profit Margin | -21.5% | -20.4% | 14.0% | 10.5% |
| Rev Growth | +14.3% | +14.3% | +9.0% | -7.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 740.24M | 740.24M | 456.20M | 455.55M |
| Total Equity | 1.23B | 1.23B | 1.50B | 1.38B |
| D/E Ratio | 0.60 | 0.60 | 0.30 | 0.33 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -51,214,842 | -42,552,125 | 190.10M | 191.59M |
| Free Cash Flow | — | — | 135.00M | 109.51M |